Abvc Biopharma (ABVC) Change in Accured Expenses (2010 - 2026)

Abvc Biopharma (ABVC) has 17 years of Change in Accured Expenses data on file, last reported at -$7265.0 in Q1 2026.

• Quarterly Change in Accured Expenses fell 118.11% year-over-year to -$7265.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $104829.0 (down 55.68% YoY) and the FY2025 annual result came in at $152207.0, changed 0.4% from the prior year.
• Change in Accured Expenses retreated to -$7265.0 in Q1 2026, from $162591.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.7 million in Q4 2022 to a low of -$146316.0 in Q1 2023.
• A 5-year average of $149723.9 and a median of -$7265.0 in 2026 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 4018.9% in 2023, down 281.25% in 2023.
• Tracing ABVC's Change in Accured Expenses over 5 years: stood at $1.7 million in 2022, then slumped by 100.58% to -$9864.0 in 2023, then soared by 1223.99% to $110870.0 in 2024, then jumped by 46.65% to $162591.0 in 2025, then tumbled by 104.47% to -$7265.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$7265.0 (Q1 2026), $162591.0 (Q4 2025), and -$33632.0 (Q3 2025), per Business Quant data.